This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Raptor Pharmaceutical To Participate In Three Upcoming Investor Conferences In June

NOVATO, Calif., June 10, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will participate in three upcoming investor conferences in June.

  • Wells Fargo Healthcare Conference - Boston, June 17, 2014 at 8:50 a.m. EDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com
  • JMP Securities Healthcare Conference – New York, June 25, 2014 at 9:30 a.m. EDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com
  • Janney Capital Markets Healthcare Corporate Access Day – Boston, June 26, 2014, 8:00 a.m. to 4 p.m. EDT. Management will be available for one-on-one meetings with institutional investors.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic fatty liver disease, Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. A request for EU designation for RP103 in HD has been submitted. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com .

CONTACT: Georgia Erbez
         Chief Financial Officer
         Raptor Pharmaceutical Corp.
         (415) 408-6231
         gerbez@raptorpharma.com
         
         INVESTOR CONTACT:
         Westwicke Partners, LLC
         Robert H. Uhl
         Managing Director
         (858) 356-5932
         robert.uhl@westwicke.com
         
         MEDIA CONTACT:
         Carolyn Hawley
         Canale Communications
         (619) 849-5375
         carolyn@canalecomm.com

company logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,944.28 -126.12 -0.70%
S&P 500 2,095.33 -19.16 -0.91%
NASDAQ 4,947.5140 -69.4150 -1.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs